Anlotinib Hydrochloride: Elevating Angiogenesis and Tyrosine Kinase Research

Principle and Scientific Foundation of Anlotinib Hydrochloride

Anlotinib hydrochloride (CAS 1058157-76-8) is a novel, small-molecule multi-target tyrosine kinase inhibitor (TKI) that simultaneously targets VEGFR2, PDGFRβ, and FGFR1. Its mechanism hinges on potent inhibition of key pro-angiogenic signaling axes—VEGFR2, PDGFRβ, and FGFR1—each instrumental in orchestrating endothelial cell migration, proliferation, and neovascularization within tumor microenvironments. Downstream, anlotinib robustly suppresses the ERK signaling pathway, a central conduit for pro-survival and angiogenesis signals in cancer biology.

Recent research, notably Lin et al. (2018), has established that anlotinib delivers superior inhibition of VEGF/PDGF-BB/FGF-2-induced angiogenesis compared to established TKIs such as sunitinib, sorafenib, and nintedanib. The compound’s nanomolar-range IC₅₀ values—5.6 ± 1.2 nM (VEGFR2), 8.7 ± 3.4 nM (PDGFRβ), and 11.7 ± 4.1 nM (FGFR1)—underscore its high target selectivity and potency, critical for dissecting complex tyrosine kinase signaling pathways in cancer research.

Supplied by APExBIO, Anlotinib (hydrochloride) (SKU C8688) is optimized for reproducibility in advanced anti-angiogenic small molecule assays and is recommended for research use only.

Step-by-Step Experimental Workflow: Applied Protocols with Anlotinib Hydrochloride

1. Cell-Based Angiogenesis Assays

Anlotinib hydrochloride is most widely applied in cellular models using human vascular endothelial cells, such as EA.hy 926. Key workflows include:

• Wound Healing (Migration) Assay: Assess the compound's ability to inhibit VEGF/PDGF-BB/FGF-2-induced endothelial cell migration. After creating a scratch in a confluent cell monolayer, cells are treated with angiogenic factors ± anlotinib. Migration into the wound area is quantified over 24-48 hours, with significant reductions observed at nanomolar anlotinib concentrations (Lin et al., 2018).
• Transwell (Directional Migration) Assay: Cells seeded in the upper chamber are allowed to migrate toward a lower chamber containing angiogenic stimuli and varying concentrations of anlotinib. Migrated cells are stained and counted, revealing dose-dependent migration inhibition.
• Capillary Tube Formation Assay: EA.hy 926 or HUVECs are plated on Matrigel with VEGF/PDGF-BB/FGF-2 ± anlotinib. The number and length of capillary-like structures are quantified after 4–8 hours. Anlotinib produces a marked, concentration-dependent block in tube formation.

2. Ex Vivo and In Vivo Angiogenesis Models

• Rat Aortic Ring Assay: Anlotinib's anti-angiogenic efficacy is validated by culturing rat aortic rings in a collagen matrix with angiogenic factors. Sprout formation is significantly reduced in anlotinib-treated samples.
• Chicken Chorioallantoic Membrane (CAM) Assay: Embryonic CAMs are exposed to pro-angiogenic factors and anlotinib, leading to suppressed neovascularization and microvessel density.

3. Signaling Pathway Analysis

Western blotting or phospho-specific ELISA assays are employed to quantify the phosphorylation status of VEGFR2, PDGFRβ, FGFR1, and downstream ERK in treated cells. Anlotinib robustly attenuates phosphorylation events, confirming on-target activity and pathway modulation.

Protocol Enhancements

• Utilize serum-free or low-serum conditions to reduce background signaling.
• Titrate anlotinib concentrations (e.g., 1–100 nM) to establish dose–response relationships for each endpoint.
• Include positive controls (e.g., sunitinib, sorafenib) to benchmark performance.

Advanced Applications and Comparative Advantages

Superior Performance in Tumor Angiogenesis Inhibition

Compared to legacy TKIs, anlotinib hydrochloride demonstrates:

• Stronger inhibition of endothelial cell migration and tube formation at equivalent or lower doses (IC₅₀ for VEGFR2: 5.6 nM vs. 10–20 nM for sunitinib).
• Broader kinase selectivity—simultaneously targeting VEGFR2, PDGFRβ, and FGFR1, enabling disruption of compensatory pro-angiogenic pathways.
• Downstream ERK pathway suppression, blocking convergent survival and proliferation signals in tumor endothelium.

These features make anlotinib a gold-standard tool for tumor angiogenesis inhibition studies, mechanistic pathway dissection, and preclinical drug synergy screens.

Pharmacokinetic and Safety Profile

Anlotinib's pharmacokinetic characteristics—rapid oral absorption, high bioavailability (41–77% in dogs; 28–58% in rats), high plasma protein binding (93% in humans), and broad tissue distribution (including brain and tumor)—facilitate translational studies and in vivo modeling. Safety evaluations reveal a high median lethal dose (LD₅₀ = 1735.9 mg/kg, 14-day oral, rats), with only mild systemic toxicity and no significant organ or genetic toxicity.

Interlinking Related Scientific Resources

For researchers looking to expand their toolkit, several published resources complement and extend the applied use of anlotinib hydrochloride:

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inh... provides an in-depth discussion of anlotinib's superiority over current clinical TKIs and its reproducibility in anti-angiogenic assays—complementing the protocols described here with broader benchmarking data.
• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inh... offers a structured analysis of the compound's safety and pharmacokinetics, supporting the integration of anlotinib into preclinical workflows as described above.
• Anlotinib Hydrochloride: Unraveling Multi-Target Angiogen... delves into the unique molecular mechanisms of anlotinib, extending the mechanistic focus beyond standard product guides to advanced pathway interrogation.

Troubleshooting and Optimization Tips

Common Pitfalls and Solutions

• Variable cell response: Validate cell line authentication; passage number can affect angiogenic responsiveness. Use early-passage endothelial cells.
• Inconsistent migration/tube formation: Ensure even cell seeding, consistent Matrigel thickness, and precise timing when adding anlotinib and angiogenic factors.
• Poor solubility: Dissolve anlotinib hydrochloride in DMSO at high concentration (e.g., 10 mM stock), then dilute in assay buffer/media to ≤0.1% final DMSO.
• Off-target cytotoxicity: Titrate concentration and include a cell viability assay (MTT or CellTiter-Glo) to distinguish specific endothelial cell migration inhibition from general cytotoxicity.
• Signal pathway assessment: For robust ERK signaling pathway inhibition readouts, harvest cells rapidly after stimulation (5–30 min) and use phospho-specific antibodies validated in your cell system.

Batch-to-Batch Consistency

Source your Anlotinib (hydrochloride) exclusively from trusted suppliers like APExBIO to ensure high purity and reproducibility—a critical factor for comparative studies and multi-center collaborations.

Future Outlook: Expanding the Frontiers of Tyrosine Kinase Inhibitor Research

Anlotinib hydrochloride is rapidly becoming the benchmark VEGFR2 PDGFRβ FGFR1 inhibitor for dissecting tumor angiogenesis and resistance mechanisms. Its ability to cross the blood-brain barrier positions it for studies in brain tumors and metastatic models. Ongoing research is exploring combinatorial regimens pairing anlotinib with immunotherapies or chemotherapeutics, leveraging its profound effect on the tumor microvasculature to boost drug delivery and immune cell infiltration.

High-throughput screening platforms can harness anlotinib’s selectivity to identify synergistic drug partners or unravel compensatory signaling networks. Further, its safety and PK profile support translational research, including patient-derived xenograft (PDX) and orthotopic tumor models.

In summary, anlotinib hydrochloride provides cancer researchers with a high-precision, reproducible tool for probing the nuances of angiogenesis and tyrosine kinase signaling pathway modulation, paving the way for innovative anti-angiogenic strategies and next-generation therapeutic development.